Invitro Study Webinar

Category 1 Focus Group Steering Committee

This message announces an informative invitro study webinar which will benefit all participants. I encourage all of you to attend the webinar and January meeting.

Category 1 in vitro abuse deterrence testing has grown into its own field of science.

It is not similar to other in vitro studies we perform in the pharmaceutical industry and it also involves different challenges, data and people than what is obtained from Category 2-4 abuse deterrent testing. Therefore, a focus group specifically addressing issues related to Category 1 testing was formed. We have had two successful meeting so far and the 3rd event is to take place in Jan 2018. The event is more relevant than ever as the FDA has made the Final Guidance to Industry for labeling and approval of generic ADF products, which will be an important topic for discussion.

During this webinar the audience will learn what can be considered “state of the art” and what can be relevant in the future for Category 1 tests – also in light of the new “Generic ADF Guideline”. The webinar will be a preparation for the 3rd Category One Focus Group meeting. Therefore, the webinar will be interactive with live chat, polls and questions. Topics of interest will be fed into the working group sessions during the meeting in January.

Participants of the webinar will receive a promotion code for the registration fee for the 3rd Category 1 Focus Group Meeting in January 2018.

Register Here

After registering, you will receive a confirmation email containing information about joining the webinar.

We hope you join us for this pre-meeting webinar.

Sincerely,
-Category 1 Focus Group Steering Committee
http://www.cat1focusgroup.com/3rdmeeting/

This email and any files transmitted with it are intended only for the person or entity to which it is addressed and may contain confidential and/or privileged material. Any review, transmission, re-transmission, dissemination or other use of, or taking of any action in reliance upon this information by persons or entities other than the intended recipient is prohibited. If you have received this email in error, please notify the sender by email or phone (800-235-4890), do not read the contents, delete and destroy this message and its attachments.